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1. Supplementary Materials and methods 
1.1 General 
Solvents were purified and dried by standard procedures prior to use; petroleum ether of boiling 
range 60 – 80 oC was used. All reactions were performed under an argon atmosphere. Flash 
chromatography was carried out using Merck Kieselgel (230 – 400 mesh). Thin layer 
chromatography was performed on silica gel and was visualized by staining with KMnO4. NMR 
spectra were recorded on Varian Mercury spectrometer (600, 400 and 200 MHz) with chemical 
shifts values (δ) in ppm relative to TMS as internal standard. LC/MS were performed on Waters 
2695 Alliance instrument, column: phenomenex, Gemini 5u C18 11OA, 50x2 mm, 5 µm; mobile 
phase: acetonitrile –0.1 % aq. HCOOH. Reagents and starting materials were obtained from 
commercial sources and used as received. (S)-3-Amino-N-cyclopropyl-2-hydroxypentanamide 
hydrochloride was prepared according to the literature method (Han et al., 2003). Tert-butyl 3-
(3-amino-2-hydroxybutanamido) propanoate was prepared by analogy. 
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1.2. Synthetic schemes for peptidic ketoamide KS-182, KS-466 and peptidic aminoalcohol 
KS-378 
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Scheme 1. Reagents and conditions: (i) Fmoc-Thr(tBu)-OH, EDCI, HOBt, DIEA, DCM, r.t., 8 
h; (ii) 4-(aminomethyl) piperidine, DCM, r.t., 1 h; (iii) Fmoc-Ile-OH, EDCI, HOBt, DIEA, 
DCM, r.t., 8 h; (iv) 4-(aminomethyl) piperidine, (v) Fmoc-Lys(Boc)-OH, EDCI, HOBt, 
DIEA, DCM, (vi) 4-(aminomethyl) piperidine, r.t., 8 h; (vii) acetic anhydride, pyridine, 
DMF, r.t., 8 h; (viii) LiOH, THF : H2O (20:1), r.t., 5 h; (ix) (S)-3-amino-N-cyclopropyl-2-
hydroxypentanamide hydrochloride, EDCI, HOBt, DIEA, DCM, r.t., 8 h; (x) Dess-Martin 
periodinane, NMP, r.t., 23 h, (xi) TFA : DCM (1:1), r.t., 2 h, then HCl in Et2O. 
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Scheme 2. Reagents and conditions: (i) tert-butyl 3-(3-amino-2-hydroxybutanamido)-propano-
ate, EDCI, HOBt, DIEA, DCM, r.t., 8 h; (ii) Dess-Martin periodinane, NMP, r.t., 23 h, (iii) 
TFA : DCM (1:1), r.t., 2 h, then HCl in Et2O. 
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Scheme 3. Reagents and conditions: (i) TFA : DCM (1:1), r.t., 2 h, then HCl in Et2O. 
 
1.3. Description of experiments  
Synthesis of (10S,13S,16S,19S)-methyl-10-acetamido-16-((R)-1-tert-butoxyethyl)-13-sec-
butyl-2,2,19-trimethyl-4,11,14,17-tetraoxo-3-oxa-5,12,15,18-tetraazaicosan-20-oate (2) 
O
AcNH
N
H
O
N
H
O
Me
MetBuO
N
H
Me
Me
O
OMe
NHBoc 2 A mixture of Fmoc-Thr(tBu)-OH (1.00 g, 2.5 mmol), Ala-
OMe*HCl (0.38 g, 2.7 mmol), EDCI (0.43 g, 2.7 mmol) and HOBt (0.37 g, 2.7 mmol) and DIEA 
(0.88 mL, 5.0 mmol) in DCM (20 ml) was stirred for 8 h at room temperature (TLC control – 
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hexane : ethyl acetate, 4:1). The reaction mixture was washed with H2O (5x10 ml) and then with 
brine (10 ml). Organic phase was dried over Na2SO4, filtrated and evaporated in vacuo. The 
residue was purified by flash chromatography on silica gel eluting with (hexane: ethyl acetate, 
4:1) to provide Fmoc-Thr(tBu)-Ala-OMe (0.95 g, 95%) as a colourless crystalline compound. 
LC/MS: 484 (M+1). 
Intermediate (0.95 g, 2.0 mmol) was dissolved in DCM (20 mL) and 4-aminomethyl 
piperidine (0.89 g, 7.8 mmol) was added to the solution. The resulting mixture was stirred for 1 h 
at room temperature, during this time the suspension was formed. The mixture was filtered and 
the solution obtained was washed with 10% (w/v) aqueous phosphate buffer (pH 5.5, 3x5 mL). 
Organic phase was separated, dried over Na2SO4, filtered and evaporated in vacuo to obtain crude 
Thr-Ala-OMe (0.42 g, 82%) as a yellowish solid.  
To the solution of Thr(tBu)-Ala-OMe (0.42 g, 1.6 mmol) in DCM (20 mL), Fmoc-Ile-OH 
(0.50 g, 1.5 mmol), EDCI (0.25 g, 1.6 mmol), HOBt (0.21 g, 1.6 mmol) and DIEA (0.38 mL, 2.1 
mmol) were added in the given order and the resulting mixture was stirred for 8 h at room 
temperature (TLC control- hexane : ethyl acetate, 4:1). The reaction mixture was washed with 
H2O (5x10 ml) and then with brine (10 ml). Organic phase was dried over Na2SO4, filtrated and 
evaporated in vacuo. The residue was purified by flash chromatography on silica gel eluting with 
hexane : ethyl acetate (4:1) to provide Fmoc-Ile-Thr-Ala-OMe (0.52 g, 58%) as a colourless 
crystalline compound. LC/MS: 597 (M+1). 
Intermediate (0.52 g, 0.87 mmol) was dissolved in DCM (20 ml) and 4-aminomethyl 
piperidine (0.39 g, 3.4 mmol) was added to the solution. The resulting mixture was stirred for 1 h 
at room temperature, during this time the suspension was formed. The mixture was filtered and 
the solution obtained was washed with 10% (w/v) aqueous phosphate buffer (pH 5.5, 3x5 mL). 
Organic phase was separated, dried over Na2SO4, filtered and evaporated in vacuo to obtain 
crude Ile-Thr(tBu)-Ala-OMe (0.31 g, 60 %) as a yellowish solid.  
To the solution of Ile-Thr(tBu)-Ala-OMe (0.31 g, 0.83 mmol) in DCM (20 mL), Fmoc-
Lys(Boc)-OH (0.22 g, 0.46 mmol) , EDCI (0.080 g, 0.51 mmol), HOBt (0.069 g, 0.51 mmol) and 
DIEA (0.09 mL, 0.56 mmol) were added in the given order and the resulting mixture was stirred 
for 8 h at room temperature (TLC control - hexane: ethyl acetate, 4:1). The reaction mixture was 
washed with H2O (5x10 ml) and then with brine (10 ml). Organic phase was dried over Na2SO4, 
filtrated and evaporated in vacuo. The residue was purified by flash chromatography on silica gel 
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eluting with hexane: ethyl acetate, 1:1 to provide Fmoc-Lys(Boc)-Ile-Thr(tBu)-Ala-OMe (0.26 g, 
61%) as a colourless crystalline solid. LC/MS: 825 (M+1) 
Intermediate (0.26 g, 0.31 mmol) was dissolved in DCM (20 ml) and 4-aminomethyl 
piperidine (0.14 g, 1.26 mmol) was added to the solution. The resulting mixture was stirred for 1 
h at room temperature, during this time the suspension was formed. The mixture was filtered 
through and the solution obtained was washed with 10% (w/v) aqueous phosphate buffer (pH 
5.5, 3x5 mL). Organic phase was separated, dried over Na2SO4 filtered and evaporated in vacuo 
to obtain a crude Lys(Boc)-Ile-Thr(tBu)-Ala-OMe (0.18 g, 96%) as a yellowish solid. 
Pyridine (0.026 mL, 0.32 mmol) and Ac2O (0.031 mL, 0.32 mmol) were added to the solution 
of Lys(Boc)-Ile-Thr(tBu)-Ala-OMe (0.18 g, 0.30 mmol) in DCM (20 mL) and the mixture stirred 
for 1 h at room temperature (TLC control- hexane: ethyl acetate, 4:1). The reaction mixture was 
washed with H2O (5x10 ml) and then with brine (10 ml). Organic phase was dried over Na2SO4, 
filtrated and evaporated in vacuo. The residue was purified by flash chromatography on silica gel 
eluting with ethyl acetate to provide with 2 (0.14 g, 73 %) as a colourless crystalline compound. 
1H NMR : (400 MHz; DMSO-d6;TMS) δ: 0.78-0.80 (8H, m); 0.96 (3H, d, 6.0 Hz); 1.07 (9H, 
s); 1.10-1.40 (18H, m); 1.52 (1H, m); 1.71 (3H; s); 2.81 (2H, m); 3.56(3H, s); 3.98-3.99 (1H, m); 
4.19-4.26 (5H, m); 6.68 (1H, m),7.58 (1H, d, 8.8 Hz); 7.84-7.93 ppm (3H, m). LC/MS: 645 
(M+1) 
 
Synthesis of (10S,13S,16S,19S)-10-acetamido-16-((R)-1-tert-butoxyethyl)-13-sec-butyl-
2,2, 19-trimethyl-4,11,14,17-tetraoxo-3-oxa-5,12,15,18-tetraazaicosan-20-oic acid (3) 
O
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3 A mixture of 2 (0.14 g, 0.21 mmol), LiOH (0.051 g, 2.1 mmol) in 
THF : H2O (20:1, 10 mL) was stirred at room temperature for 3 h and then acidified to pH 2 by 
addition of 1 M HCl. Water (10 mL) was added and the mixture extracted with ethyl acetate 
(10x3 mL). Organic phase was washed with brine, dried over Na2SO4 and evaporated in vacuo to 
provide compound 3 as a colourless solid (0.12 g, 88 %). 
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1H NMR: (400 MHz; DMSO-d6;TMS) δ: 0.76-0.80 (6H, m); 0.95 (3H, dd, 6.4 and 2.4 Hz); 1.07 
(9H, s); 1.12-1.23 (1H, m); 1.24 (1H, m); 1.71 (3H; d; 6.8 Hz); 1.32 (9H, s); 1.40-1.50 (1H, m); 
1.50-1.60 (1H, m); 1.70-1.77 (2H, m); 1.78 (3H, d, 5.2 Hz),1.95 (1H, s); 2.81 (2H, q) ; 3.13 (1H, 
d, 4.8Hz); 3.58-3.54 (2H, t, 6.8 Hz); 3.90-3.92 (1H, m); 4.14-4.22 (4H, m); 6.68 (1H, t, 4.6 Hz); 
7.58 (1H, d, 8.8 Hz); 7.68-7.73 (1H, m); 7.89-7.94 (1H, m); 8.02 (1H, d, 8.8 Hz); 12.5 ppm (1H, 
s). LC/MS : 631(M+1); 653 (M+Na). 
 
Synthesis of tert-butyl (3S,6S,9S,12S,15S)-15-acetamido-9-((R)-1-tert-butoxyethyl)-12-sec-
butyl-1-(cyclopropylamino)-3-ethyl-2-hydroxy-6-methyl-1,5,8,11,14-pentaoxo-4,7,10,13-
tetraazanonadecan-19-ylcarbamate (4) 
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4 A mixture of 3 (50 mg, 0.08 mmol), (S)-3-amino-N-
cyclopropyl-2-hydroxypentanamide hydrochloride (19 mg,0.09 mmol), EDCI (14 mg, 0.09 
mmol), HOBt (12 mg, 0.09 mmol), DIEA (20 uL, 0.1 mmol) and DCM (20 mL) was stirred at 
room temperature for 8 h. Organic phase was washed with brine, dried over Na2SO4 and 
evaporated in vacuo. The residue was purified by column chromatography on silica gel eluting 
with ethyl acetate followed by a mixture of ethyl acetate and methanol (10 : 1) to provide 
compound 4 as a yellowish solid (59 mg, 94%). 
1H NMR: (400 MHz ; DMSO-d6 ; TMS), δ: 0.47 -0.50 (2H, m); 0.52-0.61 (2H, m); 0.70-0.90 
(10H, m); 0.95-1.10 (3H, d, 6.4 Hz); 1.15-1.30 (14H, m ); 1.35 (9H, s); 1.51 (2H, m); 1.75 (1H, 
m); 1.81 (3H, s); 2.85 (2H, m); 3.78-4.00 (2H, m); 4.20-4.90 (4H, m); 6.71 (1H, t, 6.6 Hz); 7.22 
(1H, m); 7.62-7.63 (3H, m) ; 7.95 ppm (2H, m). LC/MS: 784 (M+1), 802 (M+1+H2O) 
 
Synthesis of tert-butyl (3S,6S,9S,12S,15S)-15-acetamido-9-((R)-1-tert-butoxyethyl)-12-sec-
butyl-1-(cyclopropylamino)-3-ethyl-6-methyl-1,2,5,8,11,14-hexaoxo-4,7,10,13-tetra-
azanona-decan-19-yl carbamate (5) 
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5 A stirred solution of compound 4 (25 mg, 0.02 mmol) in 
anhydrous NMP (10 ml) was cooled to 0-5oC under N2 and to this was added DMP (28 mg, 0.06 
mmol). The reaction mixture stirred for 23 h at room temperature. Organic phase was washed 
with Na2S2O3 (3x5 mL), NaHCO3 (3x5 mL), H2O (3x5 mL), dried over Na2SO4 and evaporated 
in vacuo. The residue was purified by column chromatography on silica gel ethyl acetate 
followed by a mixture of ethyl acetate and methanol (10 : 1) to provide 5 as a yellowish solid (17 
mg, 68%). 
1H NMR: (400 MHz ; DMSO-d6 ; TMS), δ: 0.57 -0.66 (2H, m); 0.80-0.90 (8H, m); 0.97-0.99 
(3H, d, 6.4 Hz); 1.12-1.24( 13H, m); 1.37-1.60 ( 13H, m ); 1.76-1.87 (5H, m); 2.73-2.75 (1H, m); 
2.85-2.87 (2H, m); 3.94-3.95 (1H, m); 4.21-4.38 (4H, m); 4.86-4.87 (1H, m); 6.71-6.74 (1H, m); 
7.60-7.61 (1H, m); 7.62-7.63 (1H, m); 7.95 (1H, d, 8 Hz); 8.05-8.10 (1H, m); 8.14 (1H, t, 6.6 
Hz); 8.72 ppm (1H, d, 5.2 Hz). LC/MS = 783 (M+1), 805 (M+Na), 683 (M+1 - Boc). 
 
Synthesis of (S)-2-acetamido-6-amino-N-((2S,3S)-1-((2S,3R)-1-((S)-1-((S)-1-(cyclopropyl-
amino)-1,2-dioxopentan-3-ylamino)-1-oxopropan-2-ylamino)-3-hydroxy-1-oxobutan-2-yl-
amino)-3-methyl-1-oxopentan-2-yl)hexanamide hydrochloride (6) (KS-182). 
O
NH2
AcNH
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*HCl 6 (KS-182) A mixture of 5 (10 mg, 0.01 mmol) in TFA : DCM (1:1, 
10 ml) was stirred at room temperature for 2 h. The reaction mixture was concentrated in vacuo 
and treated with HCl (gass) in diethyl ether (3x2 mL, evaporation after each addition). The 
residue was treated with CH3CN (3x5 mL, the precipitate was separated by centrifugation after 
each addition) and then with treated with Et2O (3x5 mL, the precipitate was separated by 
centrifugation after each addition). The product was dried over NaOH in vacuo to provide with 
compound 6 as a yellowish crystalline material (8.1 mg, 95%). 
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1H NMR: (400 MHz; DMSO-d6; TMS), δ: 0.56 -1.06 (9H, m); 1.09-1.48 (7H, m); 1.82 (3H, s); 
2.11-2.14 (2H, m); 2.73-2.82 (3H, m ); 3.95-4.00 (4H, m); 4.21-4.23 (2H, m); 4.88 (1H, m); 7.29 
(2H, m) ; 7.70-7.83 (3H, m) ; 8.05-8.08 (1H, m); 8.71-8.76 ppm (1H, m). LC/MS: 626 (M+1) 
 
Synthesis of (10S,13S,16S,19S,22SR,23SR)-tert-butyl 10-acetamido-16-((R)-1-tert-
butoxyethyl)-13-sec-butyl-23-hydroxy-2,2,19,22-tetramethyl-4,11,14,17,20,24-hexaoxo-3-
oxa-5,12,15,18,21,25-hexaazaoctacosan-28-oate 7 
O
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7 A mixture of 3 (100 mg, 0.15 mmol), tert-butyl 3-
(3-amino-2-hydroxybutanamido)propanoate (19 mg, 0.18 mmol), EDCI (14 mg, 0.18 mmol), 
HOBt (12 mg, 0.18 mmol), DIEA (33 uL, 0.18 mmol) and DMF (20 mL) was stirred at room 
temperature for 8 h. Organic phase was washed with brine, dried over Na2SO4 and evaporated in 
vacuo. The residue was purified by column chromatography on silica gel eluting with ethyl 
acetate followed by a mixture of ethyl acetate and methanol (10 : 1) to provide compound 7 (48 
mg, 35%). 
1H NMR: (400 MHz ; DMSO-d6 ; TMS), δ: 0.70 -0.90 (9H, m); 0.92-1.00 (3H, m); 1.01-1.25 
(12H, m); 1.40-1.50 (19H, m); 1.51-1.56 (1H, m ); 1.57-1.64 (1H, m); 1.80 (3H, s); 2.40-2.45 
(2H, t, 7 Hz); 2.80-2.90 (2H, m); 3.25 (2H, t, 7 Hz); 3.84-3.93 (2H, m); 4.06-4.23 (5H, m); 5.71 
(1H, d, 5.6 Hz); 6.68 (1H, t, 5.2 Hz); 7.50-7.76 (4H, m) ; 7.90-7.93(1H, m) ppm. LC/MS: 859 
(M+1), 881 (M+Na), 759 (M-Boc+1), 645 (M-Boc-2tBu). 
 
Synthesis of (10S,13S,16S,19S,22SR)-tert-butyl 10-acetamido-16-((R)-1-tert-butoxyethyl)-
13-sec-butyl-2,2,19,22-tetramethyl-4,11,14,17,20,23,24-heptaoxo-3-oxa-5,12,15,18,21,25-
hexaazaoctacosan-28-oate (8) 
9 
 
O
NHBoc
AcNH
N
H
O
N
H
O
Me
MetBuO
N
H
Me
Me
O
N
H
N
H
O
O
Me COOtBu
8 A stirred solution of compound 7 (30 mg, 0.03 
mmol) in anhydrous NMP (10 ml) was cooled to 0-5oC under N2 and to this was added DMP (31 
mg, 0.06 mmol). The reaction mixture stirred for 23 h at room temperature. Organic phase was 
washed with Na2S2O3 (3x5 mL), NaHCO3 (3x5 mL), H2O (3x5 mL), dried over Na2SO4 and 
evaporated in vacuo. The residue was purified by column chromatography on silica gel ethyl 
acetate followed by a mixture of ethyl acetate and methanol (10 : 1) to provide 8 as a yellowish 
solid (20 mg, 66%). 
1H NMR = (400 MHz; DMSO- d6; TMS) , δ: 0.70-0.85 (6H, m); 1.82 (3H, d); 1.11 (9H, s); 1.12-1.20 
(6H, m); 1.22-1.49 (20H, m); 1.50-1.53 (2H, m); 1.60-1.63 (2H, m); 1.80 (3H, s); 1.81-1.95 (2H, m); 2.10 
(1H, s); 2.11-2.15 (2H, t, 8 Hz); 2.36-2.40 ( 2H, t, 7 Hz); 2.65 (3H, s); 2.76-2.82 (2H, m); 3.83-3.98 (1H, 
m); 4.15-4.31 (5H, m ); 4.87-4.96 (1H, d, m); 6.68 (1H, s) ; 7.56-7.58 (1H, d, 7.6 Hz); 7.65-7.81 (1H, m); 
7.90-8.03 (2H, m) ; 8.16-8.18 (1H, d, 6.4 Hz); 8.59-8.64 (1H, q, 5.6 and 11.2 Hz) ppm. LC/MS = 857 
(M+1), 757 (M+1-Boc) 
Synthesis of (4S,7S,10S,13S,16SR)-4-(4-aminobutyl)-7-sec-butyl-10-((R)-1-hydroxyethyl)-
13,16-dimethyl-2,5,8,11,14,17,18-heptaoxo-3,6,9,12,15,19-hexaazadocosan-22-oic acid (9) 
(KS-466) 
O
NH2
AcNH
N
H
O
N
H
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Me
O
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H
N
H
O
O
Me COOH
*HCl
9 (KS-466) A mixture of 8 (18 mg, 0.021 mmol) in TFA : DCM 
(1:1, 10 mL) was stirred for 2 h at room temperature and the reaction mixture was concentrated 
in vacuo. The residue was treated with CH3CN (3x5 mL, the precipitate was separated by 
centrifugation after each addition) and then with treated with Et2O (3x5 mL, the precipitate was 
separated by centrifugation after each addition). The product was dried over NaOH in vacuo to 
provide with compound 9 (10 mg, 70 %) as a yellowish crystalline solid. 
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1H NMR = (400 MHz; DMSO-d6; TMS), δ: 0.70-0.91 (8H, m); 1.82 (3H, d); 1.00-1.10 (6H, m); 
1.11-1.35 (9H, m); 1.40-1.65 (3H, m); 1.70-2.00 (5H, m); 2.15 (2H, t, 7.8 Hz); 2.44 (2H, t, 7 
Hz); 2.72-2.79 (4H, m); 3.27-3.39 (5H, m); 4.17-4.29 (4H, m); 4.94 ( 1H, m); 7.68-7.77 (3H, m); 
7.92-8.04 (1H, m); 8.60-8.68 (1H, m)  ppm. LC/MS = 644 ( M+1), 662 (M+1+H2O). 
 
Synthesis of (2S)-2-acetamido-6-amino-N-((2S,3S)-1-((2S,3R)-1-((2S)-1-((3S)-1-(cyclo-
propylamino)-2-hydroxy-1-oxopentan-3-ylamino)-1-oxopropan-2-ylamino)-3-hydroxy-1-
oxobutan-2-ylamino)-3-methyl-1-oxopentan-2-yl)hexanamide hydrochloride 10 (KS-378) 
O
NH2
AcNH
N
H
O
N
H
O
Me
MeOH
N
H
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H
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H
O
OH
Me
10 (KS-378) A mixture of 4 (10 mg, 0.012 mmol) in TFA : DCM 
(1:1, 10 mL) was stirred for 2 h at room temperature and the reaction mixture was concentrated 
in vacuo. The residue was treated with CH3CN (3x5 mL, the precipitate was separated by 
centrifugation after each addition) and then with treated with Et2O (3x5 mL, the precipitate was 
separated by centrifugation after each addition). The product was dried over NaOH in vacuo to 
provide with compound 10 (8 mg, 94.4 %) as a yellowish crystalline solid. 
1H NMR: (400 MHz; DMSO-d6; TMS), δ: 0.40-0.62 (2H, m); 0.70-0.90 (6H, m); 0.95-1.02 (2H, 
m); 1.10-1.35 (12H, m); 1.40-1.60 ( 2H, m); 1.81 (3H, s); 2.72 (1H, d, 4.8 Hz); 2.80-3.10 (2H, 
m); 3.80-4.10 (2H, m); 4.15-4.32 (3H, m); 7.63-7.80 (3H, m); 7.85-8.00 (2H, m); 8.01 ppm (1H, 
d, 10 Hz). LC/MS: 628 (M+1). 
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